tert-Butyl 2-Amino-4-(4-methyl-1-piperazinyl)benzoate is a pharmaceutial intermediate that typically in the preparation of RXDX-101 and NMS-E628, an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity.
Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. 
Enrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. 
ALK inhibitors in non-small cell lung cancer: The latest evidence and developments. 
 E.Ardini, et al, Mol. Cancer Ther., 2009, 8(12 Suppl.), pp A244-A244.
 S.Siena, et al, Eur. J. Cancer, 2015, 51(3 Suppl.), pp S724-S725.